Spectranetics out of Colorado Springs, Colorado won the CE Mark in Europe to bring to market its*AngioSculptX Drug-Coated PTCA (percutaneous transluminal coronary angioplasty) Scoring Balloon Catheter. Originally developed by AngioScore, a company purchased by Spectranetics, the device is a drug coated version of the company’s proven AngioSculpt PTCA scoring balloon Catheter and is indicated for treatment of*coronary artery ste**sis,*which includes*in-stent reste**sis.
“AngiosculptX represents a unique coronary scoring tech**logy that incorporates a drug coating. Given its clinical results, it is a significant advancement in therapy options for patients,” said Professor Bru** Scheller of Saarlandes University Clinic in Homburg, Germany, in a statement.
08-12-2016, 08:34 PM
AngioSculptX, a New Drug-Coated PTCA Catheter **w Available in Europe
العرض الشجري